1. Academic Validation
  2. Novel monocyclic amide-linked phenol derivatives without mitochondrial toxicity have potent uric acid-lowering activity

Novel monocyclic amide-linked phenol derivatives without mitochondrial toxicity have potent uric acid-lowering activity

  • Bioorg Med Chem Lett. 2021 May 15:40:127900. doi: 10.1016/j.bmcl.2021.127900.
Junichiro Uda 1 Seiichi Kobashi 2 Naoki Ashizawa 3 Koji Matsumoto 3 Takashi Iwanaga 3
Affiliations

Affiliations

  • 1 Medical R&D Division, FUJI YAKUHIN CO., LTD., Laboratory 1, 1-32-3, Nishiomiya, Nishi-ku, Saitama-shi, Saitama 331-0078 Japan. Electronic address: [email protected].
  • 2 Medical R&D Division, FUJI YAKUHIN CO., LTD., Laboratory 1, 1-32-3, Nishiomiya, Nishi-ku, Saitama-shi, Saitama 331-0078 Japan.
  • 3 Medical R&D Division, FUJI YAKUHIN CO., LTD., Laboratory 2, 636-1, Iidashinden, Nishi-ku, Saitama-shi, Saitama 331-0068, Japan.
Abstract

Although benzbromarone (BBR) is a conventional, highly potent uricosuric drug, it is not a standard medicine because it causes rare but fatal fulminant hepatitis. We transformed the bis-aryl ketone structure of BBR to generate novel monocyclic amide-linked phenol derivatives that should possess uric acid excretion activity without adverse properties associated with BBR. The derivatives were synthesized and tested for uric acid uptake inhibition (UUI) in two assays using either urate transporter 1-expressing cells or primary human renal proximal tubule epithelial cells. We also evaluated their inhibitory activity against mitochondrial respiration as a critical mitochondrial toxicity parameter. Some derivatives with UUI activity had no mitochondrial toxicity, including compound 3f, which effectively lowered the plasma uric acid level in Cebus apella. Thus, 3f is a promising candidate for further development as a uricosuric agent.

Keywords

Benzbromarone; Mitochondrial toxicity; Primary human renal proximal tubule epithelial cells Dotinurad; Uricosurics.

Figures